Learn about Initial Steps for COVID-19 Vaccine Distribution
COVID-19 Vaccination Information Released on December 9, 2020 from the Governor’s Office
Doses will then be redistributed for access to 74 hospitals across all 14 counties for front line medical workers. The next 40,000 doses of Pfizer vaccine will be allocated to the Federal Pharmacy Program to begin vaccinating staff and residents of skilled nursing facilities, rest homes and assisted living residences.
Vaccine is being prioritized for these groups to maximize life preservation and to support the health care system. Based on information at this time, Massachusetts is expecting 300,000 first doses of the vaccine to be delivered by the end of December. The first vaccines, manufactured by Moderna and Pfizer, will require two doses administered 3-4 weeks apart. Click here to view the administration’s vaccine website: www.mass.gov/COVIDvaccine
While all delivery dates and quantities are subject to change due to ongoing federal approval and allocation, the Administration plans to receive and distribute over 2 million doses to priority population groups by the end of March. In collaboration with the COVID-19 Vaccine Advisory Group, the Administration designated groups of medical workers, first responders and residents most at risk for serious illness to receive the vaccine before the general population. The Vaccine Advisory Group is made up of leading medical, infectious disease and public health experts as well as representatives from communities of color and representatives of high-risk populations. Communities of color and at-risk populations are prioritized throughout the process to maximize life preservation and to prevent serious complications from COVID related illnesses.
Anticipated Vaccination Phases and Timeline:
Phase One (December 2020-February 2021)
Phase Two (February 2021-April 2021)
Phase Three (April 2021- ) Vaccine available to general public
Vaccines go through extensive testing, more than any pharmaceuticals, including extensive testing in clinical trials. The FDA, which approves the vaccine, and the CDC’s Advisory Committee on Immunization Practices (ACIP), which will make its recommendation for use, must ensure any vaccine is both safe and effective for the public before approval and distribution.